P/B
3,3
Celldex Therapeutics
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
$2.3B
Market Cap • 10/9/2026
1983
(43 years)
Founded
1986
(40 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
14856
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
9,1
EPS
—
Market Cap
Market Cap
2,3B
EV
1,6B
EV/Revenue
10353,1
EV/EBITDA
-5,1
EV/EBIT
-5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-13,9%
Total Yield
-13,9%
Payout
0%
Retained Earnings
-2B
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
176460%
Capex/Revenue
4138,6%
Capex/D&A
192,6%
Capex/OCF
-2,8%
SBC/OCF
—
% PPE
1,9%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
-55,1%
CAGR Op. Income 5Y
36,3%
CAGR Net Income 5Y
35,4%
CAGR EPS 5Y
21,1%
CAGR OCF 5Y
38%
Leverage
N.D./EBITDA
2,2
Debt/Equity
0%
Current Ratio
11,8
Quick Ratio
11,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!